Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 4/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.45 |
| ▸ | PPARA | Q07869 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13197819 | 0.92 | PPARA (0.46) | NAMPTEPHX2PPARALMNA | |
| SCHEMBL13197847 | 0.92 | KDM4E (0.51) | NAMPTEPHX2PPARALMNASMN1; SMN2 | |
| SCHEMBL13197974 | 0.90 | NAMPT (0.49) | NAMPTEPHX2PPARASMN1; SMN2HDAC1 | |
| SCHEMBL13197832 | 0.88 | EPHX2 (0.54) | NAMPTEPHX2PPARALMNASMN1; SMN2 | |
| SCHEMBL2569011 | 0.88 | NAMPT (0.50) | NAMPTPOLB | |
| SCHEMBL13197839 | 0.87 | NAMPT (0.44) | NAMPTEPHX2PPARALMNASMN1; SMN2 | |
| SCHEMBL13197809 | 0.87 | EPHX2 (0.44) | NAMPTEPHX2PPARALMNASMN1; SMN2 | |
| SCHEMBL13197825 | 0.87 | EPHX2 (0.44) | NAMPTEPHX2PPARALMNASMN1; SMN2 | |
| SCHEMBL2571500 | 0.85 | EPHX2 (0.50) | EPHX2HDAC1HDAC6POLBMCHR1 | |
| SCHEMBL13197870 | 0.84 | MCHR1 (0.45) | EPHX2POLBMCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7767704-B2 | Antiviral 4-aminocarbonylamino-substituted imidazole compounds | AICURIS GMBH & CO. KG (DE) | 2010-08-03 | — | — | US | disclosed |
| US-7767704-B2 | Antiviral 4-aminocarbonylamino-substituted imidazole compounds | AICURIS GMBH & CO. KG (DE) | 2010-08-03 | — | — | US | disclosed |
| US-20080004275-A1 | Antiviral 4-Aminocarbonylamino-Substituted Imidazole Compounds | BAYER HEALTHCARE AG (DE) | 2008-01-03 | — | — | US | disclosed |
| US-20080004275-A1 | Antiviral 4-Aminocarbonylamino-Substituted Imidazole Compounds | BAYER HEALTHCARE AG (DE) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004275-A1 | Antiviral 4-Aminocarbonylamino-Substituted Imidazole Compounds | IRF3, EIF2AK2, ZC3HAV1 | NAMPT 1354/4885EPHX2 3922/4885PPARA 2490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.